SCHEMBL20660767

SCHEMBL20660767

Cc1cc(N)ccc1-c1ccc2cc(F)ccc2n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 3/20 0.50
▸ LMNA P02545 2/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ POLB P06746 1/20 0.46
▸ CASP6 P55212 1/20 0.46
▸ AR P10275 3/20 0.41
▸ PLAU P00749 1/20 0.41
▸ TLR8 Q9NR97 1/20 0.39
▸ MAOA P21397 2/20 0.38
▸ MAOB P27338 1/20 0.38
▸ TTR P02766 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ F2 P00734 1/20 0.37
▸ CHRM2 P08172 1/20 0.37
▸ HTR1A P08908 1/20 0.37
▸ ADRA2A P08913 1/20 0.37
▸ ADORA3 P0DMS8 1/20 0.37
▸ DRD1 P21728 1/20 0.37
▸ ACHE P22303 1/20 0.37
▸ PTGS1 P23219 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20660449 0.81 BACE1 (0.49) BACE1LMNAKDM4EPOLBCASP6
SCHEMBL20660528 0.80 BACE1 (0.51) BACE1LMNAKDM4EPOLBCASP6
SCHEMBL20660803 0.79 BACE1 (0.63) BACE1LMNAKDM4EPOLBCASP6
SCHEMBL20660529 0.78 BACE1 (0.49) BACE1LMNAKDM4EPOLBCASP6
SCHEMBL20660566 0.77 BACE1 (0.47) BACE1LMNAKDM4EPOLBCASP6
SCHEMBL20660718 0.77 NPBWR1 (0.44) LMNAPOLBTTRMEN1HTT
SCHEMBL20660721 0.74 BACE1 (0.54) BACE1LMNAKDM4EPOLBCASP6
SCHEMBL20660565 0.73 BACE1 (0.50) BACE1KDM4EARMAOAMAOB
SCHEMBL15831603 0.73 BACE1 (0.49) BACE1LMNAKDM4EPOLBAR
SCHEMBL5958392 0.73 MEN1 (0.54) BACE1LMNAKDM4EPOLBCASP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11548867-B2 Amido compounds as AhR modulators IDEA YA BIOSCIENCES, INC. (US) 2023-01-10 — — US disclosed
US-11548867-B2 Amido compounds as AhR modulators IDEA YA BIOSCIENCES, INC. (US) 2023-01-10 — — US disclosed
US-20220340875-A1 METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING AMIDO COMPOUNDS IDEAYA BIOSCIENCES, INC. 2022-10-27 — — US disclosed
US-20210115016-A1 AMIDO COMPOUNDS AS AhR MODULATORS IDEAYA BIOSCIENCES, INC. 2021-04-22 — — US disclosed
US-20210115016-A1 AMIDO COMPOUNDS AS AhR MODULATORS IDEAYA BIOSCIENCES, INC. 2021-04-22 — — US disclosed
WO-2020018848-A1 METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING AMIDO COMPOUNDS IDEAYA BIOSCIENCES, INC. (US) 2020-01-23 — — WO disclosed
WO-2020018848-A1 METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING AMIDO COMPOUNDS IDEAYA BIOSCIENCES, INC. (US) 2020-01-23 — — WO disclosed
WO-2019018562-A1 AMIDO COMPOUNDS AS AhR MODULATORS IDEAYA BIOSCIENCES, INC. (US) 2019-01-24 — — WO disclosed
WO-2019018562-A1 AMIDO COMPOUNDS AS AhR MODULATORS IDEAYA BIOSCIENCES, INC. (US) 2019-01-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220340875-A1 METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING AMIDO COMPOUNDS AHR, MCL1, ARNT BACE1 2063/4885LMNA 1200/4885KDM4E 1302/4885
US-20210115016-A1 AMIDO COMPOUNDS AS AhR MODULATORS AHR, ARNT, RXRB BACE1 958/4885LMNA 1969/4885KDM4E 880/4885
US-11548867-B2 Amido compounds as AhR modulators AHR, ARNT, RXRB BACE1 958/4885LMNA 1969/4885KDM4E 880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback